THE ESSENTIAL
- 20% of women with repeated miscarriages test positive for an antibody that targets their own body.
- Taking low-dose aspirin and heparin increases their chances of giving birth to a live child by 50% to 87%.
- This treatment also helps reduce the likelihood of experiencing complications during pregnancy from 50% to 6%.
“Anti-β2-glycoprotein I (β2GPI)/human leukocyte antigen (HLA)-DR antibodies may be a risk factor for recurrent pregnancy loss.” This was indicated by researchers at Kobe University (Japan). Indeed, they recently discovered that in 20% of women with recurrent miscarriages, a specific antibody targeting their own body could be detected in their blood. “The therapeutic modality for women with recurrent miscarriages and anti-β2GPI/HLA-DR antibody positivity has not been evaluated.” Faced with this observation, scientists decided to evaluate whether low-dose aspirin and/or therapies with heparin, an anticoagulant, improve patients’ pregnancy outcomes.
39 pregnant women received treatment with aspirin and low-dose heparin
To do this, the team carried out a study during which 462 women with recurrent miscarriages were recruited. However, 47 adults were actually included in the research. The participants, who were followed for two years, had to take a blood test to detect the presence of anti-β2GPI/HLA-DR antibodies. If one of these volunteers became pregnant during this period, their doctor offered them treatment with aspirin and low-dose heparin. The authors then looked at how many women who took these medications had full-term live births or pregnancy complications (preeclampsia, premature birth due to placental insufficiency) and compared the data to those of the eight patients who did not. took neither of these two medications.
Miscarriage: 87% of patients who took the treatment gave birth to a live child
According to the results, published in the journal Frontiers in Immunologywomen who received the treatment were much more likely to give birth to live children (87% did so) than those who did not receive the treatment (only 50% of whom delivered a live baby). Among live births, treatment reduced the likelihood of complications from 50% to 6%.
“The recently discovered self-targeting antibody has also been shown to be involved in infertility and recurrent implantation failure, as well as a risk factor for arterial thrombosis in women with systemic rheumatic diseases. I m “We therefore expect studies on the effectiveness of the treatment against a wider range of pathologies to produce encouraging results”concluded Kenji Tanimura, lead author of the work.
Related News :